Metro Inc (TSX:MRU)
C$ 92.53 +1.41 (+1.55%) Market Cap: 19.52 Bil Enterprise Value: 24.21 Bil PE Ratio: 19.73 PB Ratio: 2.81 GF Score: 84/100

Q2 2025 Metro Inc Earnings Call Transcript

Apr 16, 2025 / 01:00PM GMT
Release Date Price: C$101.13 (+0.25%)

Key Points

Positve
  • Metro Inc (MTRAF) reported a 5.5% increase in total sales, reaching $4.9 billion in the second quarter.
  • The company achieved a 9.8% increase in adjusted net earnings, amounting to $226.6 million.
  • Online sales grew by 26% for the quarter, driven by the expansion of click and collect services and third-party marketplaces.
  • Pharmacy division recorded solid same-store sales growth of 7%, with prescription sales up 7.8%.
  • Metro Inc (MTRAF) maintained a strong focus on local and Canadian products, which outpaced total sales growth.
Negative
  • Operating expenses were $521.3 million, representing 10.6% of sales, slightly down from 10.7% last year, but still a significant cost factor.
  • Energy costs in Ontario increased due to cold weather, impacting overall expenses.
  • The company faced increased fees related to online partnerships, affecting operating margins.
  • Depreciation and amortization expenses rose by 5.1% due to investments in supply chain and automation technology.
  • The economic environment remains uncertain, with potential impacts from tariffs and counter tariffs on consumer behavior and business operations.
Operator

Good morning ladies and gentlemen, and welcome to the Metro Inc. 2025 second quarter results conference call. (Operator Instructions) This call is being recorded on Wednesday, April 16, 2025. I would now like to turn the conference over to Mr. Sharon Kadoche. Please go ahead.

Sharon Kadoche
Metro Inc - Director, Investor Relations & Corporate Finance

Well, good morning, everyone. Thank you for joining us today. Our comments will focus on the financial results of our second quarter, which ended on March 15.

With me today is Mr. Eric La Flèche, President and CEO; François Thibault, Executive VP and CFO; Marc Giroux, Chief Operating Officer; Jean-Michel Coutu, President of the Pharmacy Division; and Nicolas Amyot, incoming CFO. The call, we will present our second quarter results and comment on its highlights. We will then be happy to take your questions.

Before we begin, I would like to remind you that we will use in today's discussion different statements that could be construed as information.

In general, any statement which

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot